The incidence of acute exacerbation (AEx) of idiopathic interstitial pneumonias related to each second-line chemotherapy regimen
| Regimen | Patients | AEx |
| Docetaxel | 72 (25.9%) | 11 (15.3%) |
| Carboplatin+paclitaxel | 31 (11.1%) | 3 (9.7%) |
| Vinorelbine | 24 (8.6%) | 6 (25%) |
| Pemetrexed | 21 (7.6%) | 6 (28.6%) |
| Amrubicin | 18 (6.5%) | 6 (33.3%) |
| S-1 | 14 (5.3%) | 0 (0%) |
| Nogitecan | 13 (4.9%) | 3 (23.1%) |
| Carboplatin+etoposide | 15 (5.4%) | 0 (0%) |
| EGFR-TKIs | 9 (3.2%) | 4 (44.4%) |
| Paclitaxel | 7 (2.5%) | 1 (14.3%) |
| Cisplatin+vinorelbine | 6 (2.2%) | 0 (0%) |
| Irinotecan | 6 (2.2%) | 0 (0%) |
| Others | 42 | 5 (12.5%) |
| Total | 278 | 45 (16.2%) |
EGFR-TKI: epidermal growth factor receptor tyrosine kinase inhibitor.